ArticleBritish journal of haematology2026

Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma.

Sohaib Irfan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.